Last reviewed · How we verify
bortezomib, dexamethasone, and thalidomide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
bortezomib, dexamethasone, and thalidomide (bortezomib, dexamethasone, and thalidomide) — Millennium Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| bortezomib, dexamethasone, and thalidomide TARGET | bortezomib, dexamethasone, and thalidomide | Millennium Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- bortezomib, dexamethasone, and thalidomide CI watch — RSS
- bortezomib, dexamethasone, and thalidomide CI watch — Atom
- bortezomib, dexamethasone, and thalidomide CI watch — JSON
- bortezomib, dexamethasone, and thalidomide alone — RSS
Cite this brief
Drug Landscape (2026). bortezomib, dexamethasone, and thalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/bortezomib-dexamethasone-and-thalidomide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab